What is NDC 79952-110?

79952-110 is the product NDC for Zynlonta (loncastuximab tesirine), Loncastuximab tesirine 10 mg/2mL injection, powder, lyophilized, for solution, listed with the FDA by ADC Therapeutics America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Zynlonta (Loncastuximab tesirine).

ADC Therapeutics America, Inc., NDC labeler code 79952. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Zynlonta?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Zynlonta NDC 79952-110 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)79952-110Labeler and product segments. Claims need a package NDC.

Product NDC at billing width79952-0110Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
79952-110-01	79952011001	1 VIAL, SINGLE-DOSE in 1 CARTON (79952-110-01) / 2 mL in 1 VIAL, SINGLE-DOSEMarketed from Apr 30, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zynlonta
Generic name (nonproprietary): loncastuximab tesirine
Active ingredients: Loncastuximab tesirine — 10 mg/2mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: ADC Therapeutics America, Inc.NDC labeler code 79952
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761196
Marketing start: Apr 30, 2021
Listing expires: Dec 31, 2027
Identifiers: Product ID 79952-110_6bd41585-62b9-4761-859b-759672bfd679SPL ID 6bd41585-62b9-4761-859b-759672bfd679SPL set ID af54af12-3edf-4301-8bc5-0446bc813c1dRxCUI 2540969, 2540974UNII 7K5O7P6QIUUPC 0379952110014

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N479952011001 followed by a unit qualifier and the quantity

Package 79952-0110-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 12, 2026.

Indications (excerpt from the label)

ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory lar…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 79952-110

What is NDC 79952-110?: 79952-110 is the product NDC for Zynlonta (loncastuximab tesirine), Loncastuximab tesirine 10 mg/2mL injection, powder, lyophilized, for solution, listed with the FDA by ADC Therapeutics America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Zynlonta (Loncastuximab tesirine).
What is the active ingredient?: Loncastuximab tesirine.
Who is the labeler?: ADC Therapeutics America, Inc., NDC labeler code 79952. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Zynlonta?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Zynlonta (Loncastuximab tesirine) NDC 79952-110